...
首页> 外文期刊>Journal of biomedical nanotechnology >Mechanism of Anti-Cancer Activity of Benomyl Loaded Nanoparticles in Multidrug Resistant Cancer Cells
【24h】

Mechanism of Anti-Cancer Activity of Benomyl Loaded Nanoparticles in Multidrug Resistant Cancer Cells

机译:负载苯菌灵的纳米颗粒在多药耐药癌细胞中的抗癌机制

获取原文
获取原文并翻译 | 示例
           

摘要

Polymeric chitosan-poly(D, L-lactide-co-glycolide) nanoparticles loaded with benomyl as anticancer drug formulation against multidrug-resistant EMT6/AR1 cells were synthesized by amine-carboxylate reaction. Using transmission electron microscopy, the average size of chitosan-poly(D, L-lactide-co-glycolide) nanoparticles and benomyl-encapsulated polymeric chitosan-poly(D, L-lactide-co-glycolide) nanoparticles was estimated to be 155 +/- 20 nm and 160 +/- 25 nm, respectively. Fourier transform infrared spectroscopy revealed that poly(D, L-lactide-co-glycolide) and chitosan are linked by covalent bonds. Zeta potentials of benomyl-encapsulated polymeric chitosan-poly(D, L-lactide-co-glycolide) nanoparticles at pH 4, 7.2, and 10 were 30 +/- 1.8, 19 +/- 0.65, and -22 +/- 0.15 mV, respectively, indicating the formation of stable, hydrophilic nanoparticles. The release of benomyl from benomyl-encapsulated polymeric chitosan-poly(D, L-lactide-co-glycolide) nanoparticles followed pH-dependent kinetics. The uptake of fluorescein isothiocyanate-labeled chitosan-poly(D, L-lactide-co-glycolide) nanoparticles was concentration-dependent in both MCF-7 and multidrug-resistant EMT6/AR1 cells. EMT6/AR1 cells showed 10-fold higher resistance to benomyl compared to MCF-7 cells; in contrast, benomyl-encapsulated polymeric chitosan-poly(D, L-lactide-co-glycolide) nanoparticles effectively inhibited proliferation of MCF-7 and EMT6/AR1 cells with a half-maximal inhibitory concentration of 4 +/- 0.5 and 9 +/- 0.5 mu M, respectively. In the presence of a P-glycoprotein inhibitor, the activity of benomyl was increased, suggesting that benomyl is a substrate for P-glycoprotein. Further, benomyl-encapsulated polymeric chitosan-poly(D, L-lactide-co-glycolide) nanoparticles depolymerized microtubules both in interphase and mitosis. It blocked cell cycle progression at G2/M and induced apoptosis in EMT6/AR1 cells, suggesting that benomyl-encapsulated polymeric chitosan-poly(D, L-lactide-co-glycolide) nanoparticles have chemotherapeutic activity against multidrug-resistant cancer cells.
机译:通过胺-羧酸盐反应合成了负载苯菌灵的壳聚糖-聚(D,L-丙交酯-乙交酯)共聚物纳米粒作为抗多药耐药的EMT6 / AR1细胞的抗癌药物制剂。使用透射电子显微镜观察,壳聚糖-聚(D,L-丙交酯-乙交酯)纳米粒子和苯菌灵包封的聚合物壳聚糖-聚(D,L-丙交酯-乙交酯)纳米粒子的平均尺寸估计为155 +分别为20 nm和160 +/- 25 nm。傅里叶变换红外光谱表明,聚(D,L-丙交酯-乙交酯)和壳聚糖通过共价键相连。苯菌灵包封的聚合物壳聚糖-聚(D,L-丙交酯-乙交酯)纳米粒子在pH 4、7.2和10下的Zeta电位分别为30 +/- 1.8、19 +/- 0.65和-22 +/- 0.15 mV分别表示稳定的亲水性纳米颗粒的形成。苯菌灵包封的聚合物壳聚糖-聚(D,L-丙交酯-共-乙交酯)纳米颗粒中苯菌灵的释放遵循pH依赖性动力学。荧光素异硫氰酸酯标记的壳聚糖-聚(D,L-丙交酯-共-乙交酯)纳米颗粒的摄取在MCF-7和耐多药的EMT6 / AR1细胞中均呈浓度依赖性。与MCF-7细胞相比,EMT6 / AR1细胞对苯菌灵的抵抗力高10倍;相比之下,苯菌灵包封的聚合物壳聚糖-聚(D,L-丙交酯-乙交酯)纳米颗粒有效抑制MCF-7和EMT6 / AR1细胞的增殖,其半数抑制浓度为4 +/- 0.5和9 +分别为0.5μM。在存在P-糖蛋白抑制剂的情况下,苯菌灵的活性增加,表明苯菌灵是P-糖蛋白的底物。此外,苯菌灵包封的聚合物壳聚糖-聚(D,L-丙交酯-乙交酯共聚)纳米颗粒在相间和有丝分裂中均使微管解聚。它阻断了G2 / M时的细胞周期进程,并诱导了EMT6 / AR1细胞的凋亡,这表明苯菌灵包封的聚合物壳聚糖-聚(D,L-丙交酯-乙交酯)纳米粒对多药耐药癌细胞具有化学治疗活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号